December 2, 2014

National News Coverage for KannaLife Sciences, Inc. an MJNA Portfolio Company

News of a potential NFL lawsuit settlement and KannaLife Sciences, Inc. ("KannaLife") license from National Institutes of Health – Office of Technology Transfer ("NIH-OTT") to develop one or more cannabinoid based drugs to treat Chronic Traumatic Encephalopathy (CTE) has fueled national attention. In addition to the attention received by KannaLife and retired National Football League ("NFL") star Marvin Washington, now a key advisory board member and CTE spokesperson for KannaLife, there remain big questions for the NFL regarding its policy on prescription pain killers and its exclusionary policy on medicinal cannabis for use by players to reduce pain.

No comments:

Post a Comment